AstraZeneca PLC (AZN) Analyst Estimates Annual - Discounting Cash Flows
AZN
AstraZeneca PLC
AZN (NASDAQ)
Period Ending: 2029
12-31
2028
12-31
2027
12-31
2026
12-31
2025
12-31
2024
12-31
2023
12-31
2022
12-30
2021
12-30
2020
12-30
2019
12-30
2018
12-30
2017
12-30
2016
12-30
2015
12-30
2014
12-30
2013
12-30
2012
12-30
2011
12-30
2010
12-30
2009
12-30
2008
12-30
2007
12-30
2006
12-30
2005
12-30
2004
12-30
2003
12-30
2002
12-30
Number of Analysts 5 10 23 18 18 14 13 2 3 3 2 11 11 10 11 20 18 10 13 10 10 15 17 20 10 7 14 14
Estimated Revenue
Low 72,079 70,107 66,174 61,382 57,381 52,591 47,126 44,416 34,622 25,082 23,165 20,882 21,012 21,668 23,206 20,707 20,161 20,731 26,501 24,292 23,404 22,263 20,893 20,017 17,536 16,932 13,449 12,996
Average 75,148 70,460 66,454 62,325 58,661 53,118 49,133 44,439 36,411 26,378 24,362 21,961 22,098 22,788 24,405 25,883 25,201 25,914 33,126 30,365 29,256 27,829 26,117 25,022 21,920 21,164 16,811 16,246
High 77,599 70,813 66,733 63,408 59,421 53,485 50,736 44,462 37,290 27,014 24,950 22,491 22,631 23,337 24,993 31,060 30,241 31,096 39,751 36,438 35,107 33,395 31,340 30,026 26,304 25,397 20,173 19,495
Estimated EBITDA
Low 17,640 17,158 16,195 15,023 14,043 12,871 11,534 6,059 5,821 6,610 5,410 5,986 4,157 5,885 5,664 4,230 6,536 8,272 12,503 10,696 9,922 8,653 7,491 7,740 5,575 5,041 3,469 3,631
Average 18,392 17,244 16,264 15,253 14,357 13,000 12,025 7,574 7,276 8,263 6,762 7,482 5,196 7,357 7,081 5,288 8,169 10,341 15,629 13,370 12,402 10,817 9,364 9,675 6,969 6,301 4,336 4,538
High 18,992 17,331 16,332 15,519 14,543 13,090 12,417 9,089 8,731 9,915 8,115 8,978 6,236 8,828 8,497 6,345 9,803 12,409 18,755 16,044 14,883 12,980 11,237 11,610 8,363 7,561 5,204 5,446
Estimated EBIT
Low 9,881 9,611 9,071 8,415 7,866 7,210 6,460 -1,106 -338.2 4,093 2,227 2,823 2,496 3,919 3,391 1,384 2,688 6,056 10,092 8,297 8,083 6,416 5,759 6,195 4,314 -823.6 2,596 2,922
Average 10,302 9,659 9,110 8,544 8,042 7,282 6,735 -184.7 666.5 5,116 2,783 3,528 3,120 4,899 4,239 1,925 3,651 7,569 12,615 10,371 10,104 8,020 7,198 7,743 5,393 400 3,245 3,653
High 10,638 9,707 9,148 8,692 8,146 7,332 6,955 737 1,671 6,139 3,340 4,234 3,744 5,879 5,087 2,466 4,614 9,083 15,137 12,446 12,125 9,624 8,638 9,292 6,471 1,624 3,894 4,383
Estimated Net Income
Low 42,942 36,896 26,872 31,853 27,973 25,293 12,306 3,073 -1,072 2,553 1,043 1,768 1,867 2,836 2,309 713 1,806 4,666 7,863 5,786 5,274 4,280 3,988 4,555 3,129 2,995 1,921 2,068
Average 45,350 40,636 33,996 32,199 28,691 25,946 12,927 6,163 -238.1 3,192 1,303 2,210 2,333 3,546 2,887 1,070 2,515 5,832 9,828 7,233 6,593 5,350 4,985 5,694 3,912 3,744 2,401 2,585
High 47,273 44,377 41,121 32,545 29,409 26,598 13,547 9,253 595.6 3,830 1,564 2,652 2,800 4,257 3,464 1,428 3,225 6,998 11,794 8,679 7,912 6,420 5,982 6,833 4,694 4,492 2,881 3,102
Estimated SGA Expenses
Low 29,420 28,615 27,010 25,054 23,421 21,466 19,236 15,820 12,961 10,545 8,038 8,700 14,969 10,936 18,231 8,452 19,394 7,303 9,081 7,922 8,367 7,916 7,468 7,065 5,960 6,415 4,590 4,527
Average 30,673 28,760 27,124 25,439 23,944 21,681 20,055 19,776 16,202 13,181 10,048 10,875 18,712 13,670 22,789 10,565 24,243 9,129 11,352 9,903 10,459 9,895 9,335 8,831 7,449 8,019 5,738 5,659
High 31,674 28,904 27,239 25,882 24,254 21,831 20,709 23,731 19,442 15,818 12,057 13,050 22,454 16,403 27,347 12,678 29,091 10,955 13,622 11,883 12,550 11,873 11,202 10,597 8,939 9,623 6,885 6,791
Estimated EPS
Low 13.74 11.8 8.6 10.19 8.95 8.09 3.94 3.14 2.43 1.96 1.68 1.58 1.77 1.97 1.99 1.67 1.95 2.25 2.85 2.24 2.03 1.61 1.39 1.39 0.85 0.83 0.49 0.64
Average 14.51 13 11.57 10.28 9.17 8.21 4.16 3.36 2.59 2.09 1.79 1.69 1.89 2.11 2.12 2.09 2.44 2.8 3.56 2.8 2.54 2.02 1.74 1.74 1.07 1.05 0.61 0.8
High 15.12 14.2 13.15 10.41 9.41 8.51 4.33 3.46 2.67 2.16 1.85 1.74 1.95 2.17 2.19 2.51 2.93 3.35 4.27 3.36 3.05 2.43 2.09 2.09 1.29 1.27 0.73 0.96
discounting cash flows home logo

Discounting Cash Flows

Are you finding our services helpful? Review us on trustpilot logo Trustpilot
Have a question? Contact us
Want to become our sponsor?
Check out our Affiliate Program